Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma

International Journal of Cancer

Volumn 128, Issue 4, 2011, Pages 787-796

  Gwak, Ho Shin ^a,c   Shingu, Takashi ^a   Chumbalkar, Vaibhav ^a   Hwang, Yeo Hyeon ^a   Dejournett, Robert ^a,d   Latha, Khatri ^a   Koul, Dimpy ^a   Alfred Yung, W K ^a   Powis, Garth ^a   Farrell, Nicholas P ^b   Bögler, Oliver ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c National Cancer Center   (South Korea)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; autophagy; glioblastoma; PI3 kinase; platinum

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; BBR 3610; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLATINUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG POTENTIATION; GLIOBLASTOMA; GLIOMA CELL; GROWTH INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLIOMA; GONANES; HUMANS; MALE; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 78650623482     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25394     Document Type: Article

References (34)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
2. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-24.
3. Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH,. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 2005; 75: 173-80.
4. Farrell N,. Polynuclear platinum drugs. Met Ions Biol Syst 2004; 42: 251-96.
5. Perego P, Gatti L, Caserini C, Supino R, Colangelo D, Leone R, Spinelli S, Farrell N, Zunino F,. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. J Inorg Biochem 1999; 77: 59-64.
6. Servidei T, Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C, Riccardi R,. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer 2001; 37: 930-8.
7. Roberts JD, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L, Farrell N,. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J Inorg Biochem 1999; 77: 47-50.
8. Roberts JD, Peroutka J, Farrell N,. Cellular pharmacology of polynuclear platinum anti-cancer agents. J Inorg Biochem 1999; 77: 51-7.
9. Harris AL, Yang X, Hegmans A, Povirk L, Ryan JJ, Kelland L, Farrell NP,. Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. Inorg Chem 2005; 44: 9598-600.
10. Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Vigano L, Gatti A, Minoia C, Liati P, Van den Bosch S, et al. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann Oncol 2000; 11: 977-83.
11. Billecke C, Finniss S, Tahash L, Miller C, Mikkelsen T, Farrell NP, Bögler O,. Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. Neuro Oncol 2006; 8: 215-26.
12. McGregor TD, Hegmans A, Kasparkova J, Neplechova K, Novakova O, Penazova H, Vrana O, Brabec V, Farrell N,. A comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase II clinical agent BBR3464. J Biol Inorg Chem 2002; 7: 397-404.
13. Gatti L, Perego P, Leone R, Apostoli P, Carenini N, Corna E, Allievi C, Bastrup U, De Munari S, Di Giovine S, Nicoli P, Grugni M, et al. Novel bis-platinum complexes endowed with an improved pharmacological profile. Mol Pharm 2010; 7: 207-16.
14. Manzotti C, Nicoli P, Torriani D, Menta E, Farrell N, Pezzoni G,. Polynuclear platinum complexes: a new class of anticancer agents. Presented at the 6th World Congress on Advances in Oncology, Crete, Greece, 2001.
15. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Gene Dev 2007; 21: 2683-710.
16. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G,. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005; 4: 1349-57.
17. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G,. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004; 3: 763-72. (Pubitemid 39193758)
18. Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L, Powis G,. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther 2009; 8: 94-100.
19. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
20. Ito H, Aoki H, Kuhnel F, Kondo Y, Kubicka S, Wirth T, Iwado E, Iwamaru A, Fujiwara K, Hess KR, Lang FF, Sawaya R, et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 2006; 98: 625-36.
21. Aoki H, Kondo Y, Aldape K, Yamamoto A, Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K, Shinojima N, Shingu T, Tamada Y, et al. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy 2008; 4: 467-75.
22. Yoon SO, Kim MM, Chung AS,. Inhibitory effect of selenite on invasion of HT1080 tumor cells. J Biol Chem 2001; 276: 20085-92.
23. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF,. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000; 92: 326-33.
24. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME,. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41.
25. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ,. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-91.
26. Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang HJ,. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56: 5079-86.
27. Powis G, Ihle NT, Yung WK,. Inhibiting PI-3-K for glioma therapy. Cell Cycle 2009; 8: 335.
28. Powis G, Ihle N, Kirkpatrick DL,. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 2006; 12: 2964-6.
29. Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, et al. A novel charged trinuclear platinum complex effective against cisplatin- resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999; 80: 1912-19.
30. Zerzankova L, Suchankova T, Vrana O, Farrell NP, Brabec V, Kasparkova J,. Conformation and recognition of DNA modified by a new antitumor dinuclear Pt(II) complex resistant to decomposition by sulfur nucleophiles. Biochem Pharmacol 2010; 79: 112-21.
31. Kondo Y, Kanzawa T, Sawaya R, Kondo S,. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5: 726-34.
32. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, Tsujimoto Y,. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004; 6: 1221-8.
33. Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, Kondo S,. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005; 24: 980-91.
34. Network TCGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.